BEACON-HCC offers a new approach to HCC treatment allocation, with key differences from the updated BCLC framework.
News|Articles|August 4, 2026
5 Hepatology Headlines You Missed in July 2026
Author(s)Alex Hillenbrand
Fact checked by: Chelsie Derman
Hepatology in July 2026: Odevixibat misses phase 3 primary endpoint, zabopegdutide shows early MASH benefit, plus a new Wilson disease NDA
Advertisement
Advertisement
July brought mixed trial results across hepatology, a new regulatory filing, and fresh data on gaps in patient awareness.
Related to this article
Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the FDA's recent approval of Bayer's finerenone in concomitant CKD and T1D.
The FDA has granted Priority Review to dersimelagon for EPP and XLP, setting a PDUFA date for late February 2027 as LEO Pharma completes its acquisition from Tanabe Pharma.
What lonvo-z is, how it works, and what a Priority Review designation means for the HAE gene-editing therapy.
Neal Bhatia, MD, weighs the newly approved Ameluz PDT regimen for sBCC against Mohs surgery, citing its 66% composite response rate.
The resubmission follows an FDA Complete Response Letter and cites human factors data showing pouch-opening time fell from 17 to 3 seconds.
The approval, backed by FINE-ONE data showing a 28% UACR reduction at 6 months, is the first new CKD treatment for this group in 3 decades.
In this Q&A, Armand explains why eczema visits spike during wildfire smoke events and how allergic patients can protect themselves.
Advertisement
Advertisement